We next focused on evaluation by immunocytochemistry of the expression of CHRM1 and CHRM3, the two muscarinic receptor subtypes expressed in GBM, although CHRM1 does not appear to be relevant for patient survival. Here, CHRM1 is linked to glioblastoma.